125 related articles for article (PubMed ID: 27266997)
21. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
22. Identification of Limonol Derivatives as Heat Shock Protein 90 (Hsp90) Inhibitors through a Multidisciplinary Approach.
Chini MG; Malafronte N; Vaccaro MC; Gualtieri MJ; Vassallo A; Vasaturo M; Castellano S; Milite C; Leone A; Bifulco G; De Tommasi N; Dal Piaz F
Chemistry; 2016 Sep; 22(37):13236-50. PubMed ID: 27492719
[TBL] [Abstract][Full Text] [Related]
23. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
24. Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors.
Dutta Gupta S; Snigdha D; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
Biomed Pharmacother; 2014 Apr; 68(3):369-76. PubMed ID: 24486109
[TBL] [Abstract][Full Text] [Related]
25. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
26. Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.
Chen D; Shen A; Li J; Shi F; Chen W; Ren J; Liu H; Xu Y; Wang X; Yang X; Sun Y; Yang M; He J; Wang Y; Zhang L; Huang M; Geng M; Xiong B; Shen J
Eur J Med Chem; 2014 Nov; 87():765-81. PubMed ID: 25313505
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
28. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
29. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
30. Structural and energetic insight into the interactions between the benzolactam inhibitors and tumor marker HSP90α.
Guo XY; Qi RP; Xu DG; Liu XH; Yang X
Comput Biol Chem; 2015 Oct; 58():182-91. PubMed ID: 26256798
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
[TBL] [Abstract][Full Text] [Related]
32. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone.
Brough PA; Barril X; Beswick M; Dymock BW; Drysdale MJ; Wright L; Grant K; Massey A; Surgenor A; Workman P
Bioorg Med Chem Lett; 2005 Dec; 15(23):5197-201. PubMed ID: 16213716
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells.
Wang X; Wang S; Liu Y; Huang D; Zheng K; Zhang Y; Wang X; Liu Q; Yang D; Wang Y
Oncol Rep; 2015 Jan; 33(1):230-8. PubMed ID: 25334086
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
[TBL] [Abstract][Full Text] [Related]
35. Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening.
Jia J; Xu X; Liu F; Guo X; Zhang M; Lu M; Xu L; Wei J; Zhu J; Zhang S; Zhang S; Sun H; You Q
PLoS One; 2013; 8(4):e59315. PubMed ID: 23565147
[TBL] [Abstract][Full Text] [Related]
36. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
37. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
38. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
39. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
